MGX
Metagenomi is an in vivo genome editing company leveraging proprietary technologies to create curative genetic medicines for patients. Founded on the science of metagenomics, the company sources genetic material from natural environments and engineers it into therapeutic tools. It focuses on high-value disease indications with well-understood biology and clearly defined clinical development and regulatory pathways, deploying a diverse and modular genome editing toolbox designed to target site-specific deletions, integrations, and corrections. Headquartered in Emeryville, California, Metagenomi aims to expand its pipeline by leveraging its genetic editing capabilities across the human genome.
No recent news for this company.
No recent deals for this company.